Active, not recruitingNot applicableNCT04108624
Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
Studying Post-transplant lymphoproliferative disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Chicago
- Principal Investigator
- Benjamin Derman, MDUniversity of Chicago
- Intervention
- Screening Phase(other)
- Enrollment
- 68 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2028
Study locations (1)
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04108624 on ClinicalTrials.govOther trials for Post-transplant lymphoproliferative disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07389616A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell LymphomaShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGNCT07470996T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NRShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE2NCT06723457Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaNorthwestern University
- RECRUITINGPHASE1, PHASE2NCT07368634Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationDaihong Liu
- RECRUITINGPHASE2NCT06954805Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)Jennifer Amengual
- RECRUITINGPHASE1, PHASE2NCT07438067EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell TransplantationDaihong Liu
- RECRUITINGPHASE2NCT06483100Measurable Residual Disease-Guided Post-Transplant Elranatamab MaintenanceWashington University School of Medicine
- ACTIVE NOT RECRUITINGNCT06422715PTLD: Multicentric Retrospective StudyFondazione Italiana Linfomi - ETS
See all trials for Post-transplant lymphoproliferative disease →